TY - JOUR
T1 - Aripiprazole in l-dopa-induced dyskinesias
T2 - A one-year open-label pilot study
AU - Meco, Giuseppe
AU - Stirpe, Paola
AU - Edito, Fabrizio
AU - Purcaro, Carlo
AU - Valente, Marcella
AU - Bernardi, Silvia
AU - Vanacore, Nicola
PY - 2009/7
Y1 - 2009/7
N2 - Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T 0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.
AB - Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T 0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.
KW - Aripiprazole
KW - L-Dopa-induced dyskinesias
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=67651149481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651149481&partnerID=8YFLogxK
U2 - 10.1007/s00702-009-0231-z
DO - 10.1007/s00702-009-0231-z
M3 - Article
C2 - 19533295
AN - SCOPUS:67651149481
VL - 116
SP - 881
EP - 884
JO - Journal of Neuro-Visceral Relations
JF - Journal of Neuro-Visceral Relations
SN - 0375-9245
IS - 7
ER -